Lilly Endowment Inc, an insider of Eli Lilly and Co (LLY), sold 93,744,884 shares of the company on November 4, 2025. The shares were sold at a price of $948.82 each, resulting in a total transaction value of approximately $88,947.21 million.
Following this transaction, Lilly Endowment Inc retains 93,744,884 shares of Eli Lilly and Co. While insider selling can occur for various reasons, including diversification and personal financial needs, such transactions do not inherently indicate negative sentiment toward the company.
Insider transactions are reported to the SEC, providing transparency into how company executives view their stock. However, investors should consider these transactions as one data point among many. Examining patterns of insider activity across multiple insiders and time periods can yield a more comprehensive understanding of market sentiment.
Eli Lilly & Co, headquartered in Indianapolis, Indiana, operates in the pharmaceuticals industry and employs approximately 47,000 full-time employees. The company focuses on the discovery, development, and sale of pharmaceutical products, with a market cap of $886.2 billion. Currently, it has a P/E ratio of 48.13 and an EPS of 20.45. Upcoming earnings reports are anticipated on April 28, 2026, with an estimated EPS of $7.07 and revenue of $17.2 billion, followed by another report on August 4, 2026, projecting an EPS of $7.70 and revenue of $17.9 billion.